Research output per year
Research output per year
Fingerprint
Dive into the research topics where Jacob Atsmon is active. These topic labels come from the works of this person. Together they form a unique fingerprint.
- 1 Similar Profiles
-
Ethics and execution of developing a 2nd wave COVID vaccine – Our interim phase I/II VSV-SARS-CoV2 vaccine experience
Levin, Y., Balakirski, N. M., Caraco, Y., Ben-Ami, E., Atsmon, J. & Marcus, H., 18 May 2021, In: Vaccine. 39, 21, p. 2821-2823 3 p.Research output: Contribution to journal › Comment/debate
Open Access -
Rapid and high seroprotection rates achieved with a tri-antigenic Hepatitis B vaccine in healthy young adults: Results from a Phase IV study
Atsmon, J., Machluf, N., Yayon-gur, V., Sabbah, C., Spaans, J. N., Yassin-Rajkumar, B., Anderson, D. E., Popovic, V. & Diaz-Mitoma, F., 22 Feb 2021, In: Vaccine. 39, 8, p. 1328-1332 5 p.Research output: Contribution to journal › Article › peer-review
Open Access -
Safety and immunogenicity of a synthetic carbohydrate conjugate vaccine against Shigella flexneri 2a in healthy adult volunteers: a phase 1, dose-escalating, single-blind, randomised, placebo-controlled study
Cohen, D., Atsmon, J., Artaud, C., Meron-Sudai, S., Gougeon, M. L., Bialik, A., Goren, S., Asato, V., Ariel-Cohen, O., Reizis, A., Dorman, A., Hoitink, C. W. G., Westdijk, J., Ashkenazi, S., Sansonetti, P., Mulard, L. A. & Phalipon, A., Apr 2021, In: The Lancet Infectious Diseases. 21, 4, p. 546-558 13 p.Research output: Contribution to journal › Article › peer-review
-
PTL401, a New Formulation Based on Pro-Nano Dispersion Technology, Improves Oral Cannabinoids Bioavailability in Healthy Volunteers
Atsmon, J., Cherniakov, I., Izgelov, D., Hoffman, A., Domb, A. J., Deutsch, L., Deutsch, F., Heffetz, D. & Sacks, H., May 2018, In: Journal of Pharmaceutical Sciences. 107, 5, p. 1423-1429 7 p.The Hebrew University of Jerusalem
Research output: Contribution to journal › Article › peer-review
-
Single-Dose Pharmacokinetics of Oral Cannabidiol Following Administration of PTL101: A New Formulation Based on Gelatin Matrix Pellets Technology
Atsmon, J., Heffetz, D., Deutsch, L., Deutsch, F. & Sacks, H., 1 Sep 2018, In: Clinical Pharmacology in Drug Development. 7, 7, p. 751-758 8 p.Research output: Contribution to journal › Article › peer-review